Document is current
Any future updates will be listed below
-
Authors
Wu, Qiu Jing
Sun, Xiujun
Teves, Lucy
Mayor, Diana https://orcid.org/0000-0001-7598-1358
Tymianski, Michael https://orcid.org/0000-0002-6311-9565
-
Funding
Funding for this research was provided by:
Canada Research Chairs
- License Information
-
More Information
Article History
Received: 25 November 2020
Accepted: 30 July 2021
First Online: 5 August 2021
Declarations
:
: Dr. Michael Tymianski (M.T.) is a Canada Research Chair (Tier 1) in Translational Stroke Research, and the CEO of NoNO Inc., a biotechnology company developing nerinetide (also termed NA-1 or Tat-NR2B9c) for clinical use. Q.J.W., X.J.S., L.T. and D.M. have no competing interests.
: All procedures performed involving animals were approved by the University Health Network animal care committee, conformed to Canadian Council of Animal Care guidelines, and ARRIVE guidelines (Kilkenny et al. ).
